Acacia Pharma Group plc Acacia Pharma To Participate In Jefferies Virtual Healthcare Conference
May 25 2021 - 5:00AM
UK Regulatory
TIDMACPH
Acacia Pharma to Participate in Jefferies Virtual Healthcare Conference
Cambridge, UK and Indianapolis, US -- 25 May 2021, 12:00 CEST: Acacia
Pharma Group plc ("Acacia Pharma", the "Group" or the "Company")
(EURONEXT: ACPH), a commercial-stage biopharmaceutical company focused
on developing and commercializing novel products to improve the care of
patients undergoing serious medical treatments such as surgery, invasive
procedures, or chemotherapy, announces that management will present a
corporate overview at the Jefferies Virtual Healthcare Conference on
Tuesday, 1 June 2021 at 08:00 ET (14:00 CEST).
A replay of the presentation will be available on the Jefferies
conference website to registered conference attendees for 30 days post
the event. Presentation slides will also be made available after the
event through the investor section (Financial Reports and Presentations)
of the Company's website, www.acaciapharma.com.
Contacts
Acacia Pharma Group plc International Media
Mike Bolinder, CEO Mark Swallow, Frazer Hall, David
Gary Gemignani, CFO Dible
+44 1223 919760 / +1 317 505 1280 Citigate Dewe Rogerson
IR@acaciapharma.com +44 20 7638 9571
acaciapharma@citigatedewerogerson.com
US Investors Media in Belgium and the Netherlands
LifeSci Advisors Chris Van Raemdonck
Irina Koffler +32 499 58 55 31
+1 917-734-7387 chrisvanraemdonck@telenet.be
ikoffler@lifesciadvisors.com
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the
development and commercialization of new products aimed at improving the
care of patients undergoing significant treatments such as surgery,
other invasive procedures, or cancer chemotherapy. The Company has
identified important and commercially attractive unmet needs in these
areas that its product portfolio aims to address.
Acacia Pharma's first product, BARHEMSYS(R) (amisulpride injection) is
available in the US for the management of postoperative nausea &
vomiting (PONV).
BYFAVO(TM) (remimazolam) for injection, a very rapid onset/offset IV
benzodiazepine sedative is approved and launched in the US for use
during invasive medical procedures in adults lasting 30 minutes or less,
such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion
UK Limited for the US market.
APD403 (intravenous and oral amisulpride), a selective dopamine
antagonist for chemotherapy induced nausea & vomiting (CINV) has
successfully completed one proof-of-concept and one Phase 2 dose-ranging
study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D
operations are centred in Cambridge, UK. The Company is listed on the
Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker
symbol ACPH.
Acacia Pharma Group plc
The Officers' Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United
Kingdom
Company number 9759376
www.acaciapharma.com
(END) Dow Jones Newswires
May 25, 2021 06:00 ET (10:00 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Apr 2023 to Apr 2024
Real-Time news about Acacia Pharma Group Plc (London Stock Exchange): 0 recent articles
More Acacia Pharma Group Plc News Articles